Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) from a hold rating to a buy rating in a research report report published on Tuesday morning. Zacks Investment Research currently has $55.00 price objective on the life sciences company’s stock.

According to Zacks, “Over the last six months, Integra Lifesciences has been trading above the broader industry. Moreover, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. On the flip side, the company exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the estimates and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes.”

A number of other analysts have also issued reports on the stock. Oppenheimer Holdings, Inc. restated a buy rating and set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, September 18th. Barclays PLC reaffirmed an equal weight rating and set a $53.00 price target (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, September 12th. Jefferies Group LLC reaffirmed a buy rating on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, September 10th. Raymond James Financial, Inc. increased their price target on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an outperform rating in a research note on Thursday, July 27th. Finally, Cantor Fitzgerald set a $65.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the stock a buy rating in a research note on Wednesday, July 26th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $54.27.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 0.61% on Tuesday, reaching $49.20. 183,225 shares of the company’s stock were exchanged. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42. The company has a market cap of $3.84 billion, a P/E ratio of 60.00 and a beta of 0.71. The firm has a 50 day moving average of $50.60 and a 200-day moving average of $49.36.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. During the same quarter last year, the business earned $0.40 earnings per share. Integra LifeSciences Holdings Corporation’s revenue was up 13.2% compared to the same quarter last year. Equities analysts expect that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Lifted to Buy at Zacks Investment Research” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-lifted-to-buy-at-zacks-investment-research/1628415.html.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. bought 10,000 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were acquired at an average price of $49.25 per share, with a total value of $492,500.00. Following the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Donald E. Morel, Jr. bought 2,500 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was acquired at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 17,550 shares of company stock worth $864,842. 21.50% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. LS Investment Advisors LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% in the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after acquiring an additional 111 shares during the period. Pinebridge Investments L.P. raised its stake in shares of Integra LifeSciences Holdings Corporation by 2.2% in the 2nd quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock valued at $435,000 after acquiring an additional 174 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Integra LifeSciences Holdings Corporation by 3.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock valued at $295,000 after acquiring an additional 187 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Integra LifeSciences Holdings Corporation by 8.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after acquiring an additional 218 shares during the period. Finally, Louisiana State Employees Retirement System raised its stake in shares of Integra LifeSciences Holdings Corporation by 1.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock valued at $1,341,000 after acquiring an additional 300 shares during the period. 84.90% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.